Aditxt (ADTX) Stock Analysis & Winston Score
Aditxt, Inc. is a small biotechnology company focused on immune system monitoring and modulation. Its main technology, called AditxtScore, is designed to measure how a person's immune system is responding — for example, after a vaccine or organ transplant. The company targets healthcare providers, researchers, and potentially pharmaceutical companies looking for better tools to track immune health. Aditxt generates revenue through laboratory services and licensing of its immune monitoring platform, though it currently spends far more than it earns, resulting in deep operating losses. The company operates primarily in the United States and has a very small market presence. Its financial metrics, including a sharply negative return on invested capital, reflect the early and high-risk stage of the business. The key challenge ahead is proving that its immune monitoring technology works well enough to attract paying customers at scale and securing enough funding to continue operations before cash runs out.
Winston Score: 6/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (1/30)
- Growth: Weak (0/20)
- Cash Flow: Weak (0/10)
- Stability: Mixed (4/10)
- Valuation: Data not available (0/10)
- Ownership: Ownership data not available (not counted) (0/15)
Key Facts
Price: $0.00
Market Cap: $3M
Sector: Healthcare
Industry: Biotechnology
Exchange: Other OTC
